MARKSANS PHARMA
|
|
BOM : 524404     NSE : MARKSANS     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
Jun 07,2023 |
Price(EOD): βΉ 89.32
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: βΉ 4,047.98 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
MARKSANS PHARMA | 6.2% | 17.1% | 89.8% |
SUN PHARMACEUTICAL INDUSTRIES | 2.7% | 5.9% | 17.9% |
DIVIS LABORATORIES | 0.5% | 4.8% | 0.3% |
CIPLA | -0.4% | 2.3% | -1.5% |
DR REDDYS LABORATORIES | 2.6% | -5.3% | 7% |
TORRENT PHARMACEUTICALS | 1.5% | 9.3% | 27.1% |
ABBOTT INDIA | 1.3% | -0.2% | 18.8% |
ZYDUS LIFESCIENCES | 0.3% | -1.9% | 41.3% |
ALKEM LABORATORIES | 0.8% | -5.8% | 9.5% |
FUNDAMENTAL ANALYSIS OF MARKSANS PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF MARKSANS PHARMA
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
15.26
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 265.32 Cr
[Latest Qtr - Mar2023 - Consolidated Results ] 2.32
P/B Calculated based on Book Value of Rs 1,745.16 Cr
[Latest Year - Mar2023 - Consolidated Results ] 2.19
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,852.14 Cr
[Latest Qtr - Mar2023 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-9% 17% 46% |
SHARE PRICE MOMENTUM OF MARKSANS PHARMA
MARKSANS PHARMA vs SENSEX
DEBT OF MARKSANS PHARMA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0.01 0 0 - |
0.04 0.02 0.03 0.03 |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF MARKSANS PHARMA
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Mar2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF MARKSANS PHARMA
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
1.28% 42.93% 31.53% 32.75% |
16.25% 72.14% 98.05% 178.93% |
QtrlyTrend |
8 | |
Latest Qtr: Mar2023 | ||
Quarterly Result Analysis → |
MARKSANS PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE SMALL CAP | 3.3% | 7.1% | 18.8% |
S&P BSE HEALTHCARE | 3.2% | 5.1% | 10% |
S&P BSE MIDSMALLCAP | 2.9% | 6.7% | 19.4% |
S&P BSE ALLCAP | 1.6% | 3.9% | 13.8% |
You may also like the below Video Courses
FAQ about MARKSANS PHARMA
Is MARKSANS PHARMA good for long term investment?
As on Jun 07,2023, the Fundamentals of MARKSANS PHARMA look Strong and hence it may be good for long term investment! See Financial Performance of MARKSANS PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is MARKSANS PHARMA UnderValued or OverValued?
As on Jun 07,2023, MARKSANS PHARMA is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of MARKSANS PHARMA ?
As on Jun 07,2023, the Intrinsic Value of MARKSANS PHARMA is Rs. 76.30 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 98.65
Fair Value [Median EV / Sales Model] : Rs. 76.30
Fair Value [Median Price / Sales Model] : Rs. 61.01
Estimated Median Fair Value of MARKSANS PHARMA : Rs. 76.30
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is MARKSANS PHARMA trading at a Premium or Discount?
As on Jun 07,2023, MARKSANS PHARMA is trading at a Premium of 17% based on the estimates of Median Intrinsic Value!